Literature DB >> 2587044

Vitreous hemorrhage after closed vitrectomy for proliferative diabetic retinopathy.

F I Tolentino1, V N Cajita, T Gancayco, S Skates.   

Abstract

The authors reviewed the medical records of 191 patients (232 eyes) who underwent closed vitrectomy for complications of diabetic retinopathy to evaluate the clinical picture of postvitrectomy hemorrhage (PVH). One hundred thirty-nine eyes (59.9%) had at least one episode of PVH (average, 1.5 per eye) that was variable in onset, not associated with a known cause in four fifths, with no noted source in two thirds, and severe in three fourths of the cases. Using logistic regression statistical analyses, the factors significantly associated with decreased incidence of PVH include older age of patient (P = 0.0004), long duration of surgery (P = 0.0002), and poor preoperative vision (P = 0.05). Of the 139 eyes with PVH, 65 (47%) had spontaneous clearing in an average of 11.3 weeks, 53 (38%) required repeat surgery, and 21 (15%) were inoperable, lost to follow-up, or refused reoperation. Postvitrectomy hemorrhage did not significantly influence the final visual outcome.

Entities:  

Mesh:

Year:  1989        PMID: 2587044     DOI: 10.1016/s0161-6420(89)32700-x

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  21 in total

1.  Intravitreal injection of bevacizumab and triamcinolone acetonide at the end of vitrectomy for diabetic vitreous hemorrhage: a comparative study.

Authors:  Dong Ho Park; Jae Pil Shin; Si Yeol Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-12-12       Impact factor: 3.117

2.  Perfluorocarbon in vitreoretinal surgery and preoperative bevacizumab in diabetic tractional retinal detachment.

Authors:  J Fernando Arevalo; Martin A Serrano; Juan D Arias
Journal:  World J Diabetes       Date:  2014-10-15

3.  Fibrovascular ingrowth and recurrent haemorrhage following diabetic vitrectomy.

Authors:  J F West; Z J Gregor
Journal:  Br J Ophthalmol       Date:  2000-08       Impact factor: 4.638

Review 4.  Current management of vitreous hemorrhage due to proliferative diabetic retinopathy.

Authors:  Jaafar El Annan; Petros E Carvounis
Journal:  Int Ophthalmol Clin       Date:  2014

5.  Six-month visual outcome after pars plana vitrectomy in proliferative diabetic retinopathy with or without a single preoperative injection of intravitreal bevacizumab.

Authors:  Amod Gupta; Reema Bansal; Vishali Gupta; Mangat R Dogra
Journal:  Int Ophthalmol       Date:  2012-03-27       Impact factor: 2.031

6.  Cryotherapy of sclerotomy sites for prevention of late post-vitrectomy diabetic hemorrhage: a randomized clinical trial.

Authors:  Morteza Entezari; Alireza Ramezani; Hamid Ahmadieh; Pejman Bakhtiari; Mehdi Yaseri; Kian Soltani
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-09-25       Impact factor: 3.117

7.  Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy.

Authors:  Ashraf M El-Batarny
Journal:  Clin Ophthalmol       Date:  2008-12

8.  Management of postvitrectomy diabetic vitreous hemorrhage with volume homeostatic fluid-fluid exchanger.

Authors:  Wen-Chuan Wu; Jen-Yu Chen; Ya-Chi Chen; Yo-Chen Chang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-05-07       Impact factor: 3.117

9.  Long-term results of vitreous surgery for proliferative diabetic retinopathy.

Authors:  P Sima; T Zoran
Journal:  Doc Ophthalmol       Date:  1994       Impact factor: 2.379

10.  Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (avastin).

Authors:  Wayne R Lo; Stephen J Kim; Thomas M Aaberg; Christopher Bergstrom; Sunil K Srivastava; Jiong Yan; Daniel F Martin; G Baker Hubbard
Journal:  Retina       Date:  2009 Jul-Aug       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.